Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 5.993
Filtrar
1.
Recurso de Internet en Inglés, Español, Portugués | LIS - Localizador de Información en Salud | ID: lis-48468

RESUMEN

A diretora da Organização Pan-Americana da Saúde (OPAS), Carissa F. Etienne, afirmou que a América Latina e o Caribe estão a caminho de atingir a meta da Organização Mundial da Saúde (OMS) de vacinar 40% de sua população antes do final do ano, mas seis países ainda não vacinaram 20%.


Asunto(s)
Américas , Vacunas contra la COVID-19
2.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-48465

RESUMEN

Milhares de mulheres que vivem um dos momentos mais especiais da vida já se vacinaram contra a Covid-19 e garantiram a proteção durante a gravidez.


Asunto(s)
Mujeres Embarazadas , Vacunas contra la COVID-19 , Vacunación
3.
Recurso de Internet en Inglés, Español, Portugués | LIS - Localizador de Información en Salud | ID: lis-48461

RESUMEN

A diretora da Organização Pan-Americana da Saúde (OPAS), Carissa F. Etienne, anunciou nesta quarta-feira (29) que o organismo internacional firmou um acordo com a Sinovac e está em negociações avançadas com outros fabricantes para adquirir vacinas contra a COVID-19 adicionais em nome de países para complementar acordos bilaterais, doações e doses recebidas por meio do mecanismo COVAX.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19
5.
J Contemp Dent Pract ; 22(7): 730-734, 2021 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-34615775

RESUMEN

AIM AND OBJECTIVE: This cross-sectional study aimed to investigate vaccine acceptance and attitude to novel coronavirus disease 2019 (COVID-19) vaccine among the general population in Saudi Arabia. MATERIALS AND METHODS: The present study was conducted among the general population in Saudi Arabia above 18 years of age. The data were collected online, by questionnaire containing 20 questions using Google form, in both Arabic and English, and were distributed to friends, families, and relatives through mail, WhatsApp groups, and Twitter. The questionnaire was randomly given out to the people living in five provinces of Saudi Arabia. RESULTS: A sum of 1,713 participants responded to the online survey. The greatest number of participants were at the age between 31 years and 45 years (36.6%) and 56.4% were females. The results showed that 74.6% have not registered for the vaccination and 44.9% responded not to take the vaccine. About 60.80% were concerned about the side effects, and 48.2% were worried about the allergic reaction to COVID-19 vaccine. About 49.1% of participants agreed that preventive measures, such as wearing mask, social distance, and using sanitizers, keep the virus away, and 53.20% believes that being exposed to disease naturally is safer for the immune system. Around 23.90% believes that vaccination cannot reduce the possibility of getting COVID-19. CONCLUSION: In the present study, the negative attitudes and afraid of the side effects of the vaccine are the most reasons for indecision and rejection about COVID-19 vaccine. For the future COVID-19 vaccination campaign not to fail, the Ministry of Saudi Arabia should closely follow the vaccination development processes, inform the public transparently, and consider public's concerns. CLINICAL SIGNIFICANCE: The results of the current study will help the Ministry of Health in Saudi Arabia to attempt proactive missions by featuring the significance of immunization to the population and empowering vaccine take-up and acceptance.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Adulto , Actitud , Estudios Transversales , Humanos , SARS-CoV-2 , Arabia Saudita , Vacunación
6.
MMWR Morb Mortal Wkly Rep ; 70(40): 1420-1424, 2021 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-34618796

RESUMEN

Most U.S. overnight youth camps did not operate during the summer of 2020 because of the COVID-19 pandemic* (1). Several that did operate demonstrated that multiple prevention strategies, including pre- and postarrival testing for SARS-CoV-2, the virus that causes COVID-19, masking, and physical distancing helped prevent the introduction and spread of COVID-19; in contrast, camps that relaxed prevention strategies, such as requiring a single prearrival test without subsequent testing, experienced outbreaks (2-4). The availability of COVID-19 vaccines for persons aged ≥12 years enabled implementation of an additional prevention strategy that was not available in summer 2020. This study assessed the number of COVID-19 cases and potential secondary spread among 7,173 staff members and campers from 50 states, 13 countries, and U.S. military overseas bases at nine independently operated U.S. summer youth camps affiliated with the same organization. The camps implemented multiple prevention strategies including vaccination, testing, podding (cohorting), masking, physical distancing, and hand hygiene during June-August 2021. Vaccination coverage was 93% among eligible persons aged ≥12 years.† All staff members (1,955) and campers (5,218) received site-specific, protocol-defined screening testing, which included prearrival testing and screening tests during the camp session (38,059 tests). Screening testing identified six confirmed COVID-19 cases (one in a staff member and five in campers) by reverse transcription-polymerase chain reaction (RT-PCR) testing (screening test positivity rate = 0.02%). Three additional cases (in two staff members and one camper) were identified based on symptoms and were confirmed by RT-PCR testing. Testing for SARS-CoV-2, isolation, and quarantine in a population with high vaccination coverage resulted in no known secondary transmission of SARS-CoV-2 identified during camp. Implementation of multicomponent strategies is critical for prevention of COVID-19 outbreaks in congregate settings, including overnight youth camps.


Asunto(s)
COVID-19/prevención & control , Acampada , Control de Enfermedades Transmisibles/métodos , Brotes de Enfermedades/prevención & control , Adolescente , COVID-19/diagnóstico , COVID-19/epidemiología , Prueba de COVID-19/estadística & datos numéricos , Vacunas contra la COVID-19/administración & dosificación , Niño , Femenino , Higiene de las Manos , Humanos , Masculino , Máscaras , Distanciamiento Físico , SARS-CoV-2/aislamiento & purificación , Estaciones del Año , Estados Unidos/epidemiología , Cobertura de Vacunación/estadística & datos numéricos
7.
Nat Commun ; 12(1): 5730, 2021 09 30.
Artículo en Inglés | MEDLINE | ID: mdl-34593807

RESUMEN

Viral reproduction of SARS-CoV-2 provides opportunities for the acquisition of advantageous mutations, altering viral transmissibility, disease severity, and/or allowing escape from natural or vaccine-derived immunity. We use three mathematical models: a parsimonious deterministic model with homogeneous mixing; an age-structured model; and a stochastic importation model to investigate the effect of potential variants of concern (VOCs). Calibrating to the situation in England in May 2021, we find epidemiological trajectories for putative VOCs are wide-ranging and dependent on their transmissibility, immune escape capability, and the introduction timing of a postulated VOC-targeted vaccine. We demonstrate that a VOC with a substantial transmission advantage over resident variants, or with immune escape properties, can generate a wave of infections and hospitalisations comparable to the winter 2020-2021 wave. Moreover, a variant that is less transmissible, but shows partial immune-escape could provoke a wave of infection that would not be revealed until control measures are further relaxed.


Asunto(s)
COVID-19/transmisión , Evasión Inmune/genética , Modelos Biológicos , Pandemias/estadística & datos numéricos , SARS-CoV-2/patogenicidad , Adolescente , Adulto , COVID-19/epidemiología , COVID-19/inmunología , COVID-19/prevención & control , Vacunas contra la COVID-19/administración & dosificación , Simulación por Computador , Predicción/métodos , Humanos , Persona de Mediana Edad , Mutación , Pandemias/prevención & control , SARS-CoV-2/genética , SARS-CoV-2/inmunología , Procesos Estocásticos , Reino Unido/epidemiología , Vacunación/estadística & datos numéricos , Adulto Joven
8.
PLoS Med ; 18(10): e1003769, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34597298

RESUMEN

BACKGROUND: NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. METHODS AND FINDINGS: The phase 2 component of our randomized, placebo-controlled, phase 1 to 2 trial was designed to identify which dosing regimen of NVX-CoV2373 should move forward into late-phase studies and was based on immunogenicity and safety data through Day 35 (14 days after the second dose). The trial was conducted at 9 sites in Australia and 8 sites in the United States. Participants in 2 age groups (aged 18 to 59 and 60 to 84 years) were randomly assigned to receive either 1 or 2 intramuscular doses of 5-µg or 25-µg NVX-CoV2373 or placebo, 21 days apart. Primary endpoints were immunoglobulin G (IgG) anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events. A key secondary endpoint was wild-type virus neutralizing antibody response. After enrollment, 1,288 participants were randomly assigned to 1 of 4 vaccine groups or placebo, with 1,283 participants administered at least 1 study treatment. Of these, 45% were older participants 60 to 84 years. Reactogenicity was predominantly mild to moderate in severity and of short duration (median <3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose. Reactogenicity occurred less frequently and was of lower intensity in older participants. Both 2-dose regimens of 5-µg and 25-µg NVX-CoV2373 induced robust immune responses in younger and older participants. For the 2-dose regimen of 5 µg, geometric mean titers (GMTs) for IgG anti-spike protein were 65,019 (95% confidence interval (CI) 55,485 to 76,192) and 28,137 (95% CI 21,617 to 36,623) EU/mL and for wild-type virus neutralizing antibody (with an inhibitory concentration of 50%-MN50%) were 2,201 (95% CI 1,343 to 3,608) and 981 (95% CI 560 to 1,717) titers for younger and older participants, respectively, with seroconversion rates of 100% in both age groups. Neutralizing antibody responses exceeded those seen in a panel of convalescent sera for both age groups. Study limitations include the relatively short duration of safety follow-up to date and current lack of immune persistence data beyond the primary vaccination regimen time point assessments, but these data will accumulate over time. CONCLUSIONS: The study confirmed the phase 1 findings that the 2-dose regimen of 5-µg NVX-CoV2373 is highly immunogenic and well tolerated in younger adults. In addition, in older adults, the 2-dose regimen of 5 µg was also well tolerated and showed sufficient immunogenicity to support its use in late-phase efficacy studies. TRIAL REGISTRATION: ClinicalTrials.gov NCT04368988.


Asunto(s)
Vacunas contra la COVID-19/administración & dosificación , COVID-19/prevención & control , Inmunogenicidad Vacunal , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Relación Dosis-Respuesta Inmunológica , Femenino , Humanos , Inmunoglobulina G/inmunología , Masculino , Persona de Mediana Edad , SARS-CoV-2/inmunología , Glicoproteína de la Espiga del Coronavirus/inmunología , Adulto Joven
9.
Infect Dis Poverty ; 10(1): 122, 2021 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-34620243

RESUMEN

BACKGROUND: The availability of various types of COVID-19 vaccines and diverse characteristics of the vaccines present a dilemma in vaccination choices, which may result in individuals refusing a particular COVID-19 vaccine offered, hence presenting a threat to immunisation coverage and reaching herd immunity. The study aimed to assess global COVID-19 vaccination intention, vaccine characteristics influencing vaccination acceptance and desirable vaccine characteristics influencing the choice of vaccines. METHODS: An anonymous cross-sectional survey was conducted between 4 January and 5 March 2021 in 17 countries worldwide. Proportions and the corresponding 95% confidence intervals (CI) of COVID-19 vaccine acceptance and vaccine characteristics influencing vaccination acceptance were generated and compared across countries and regions. Multivariable logistic regression analysis was used to determine the factors associated with COVID-19 vaccine hesitancy. RESULTS: Of the 19,714 responses received, 90.4% (95% CI 81.8-95.3) reported likely or extremely likely to receive COVID-19 vaccine. A high proportion of likely or extremely likely to receive the COVID-19 vaccine was reported in Australia (96.4%), China (95.3%) and Norway (95.3%), while a high proportion reported being unlikely or extremely unlikely to receive the vaccine in Japan (34.6%), the U.S. (29.4%) and Iran (27.9%). Males, those with a lower educational level and those of older age expressed a higher level of COVID-19 vaccine hesitancy. Less than two-thirds (59.7%; 95% CI 58.4-61.0) reported only being willing to accept a vaccine with an effectiveness of more than 90%, and 74.5% (95% CI 73.4-75.5) said they would accept a COVID-19 vaccine with minor adverse reactions. A total of 21.0% (95% CI 20.0-22.0) reported not accepting an mRNA vaccine and 51.8% (95% CI 50.3-53.1) reported that they would only accept a COVID-19 vaccine from a specific country-of-origin. Countries from the Southeast Asia region reported the highest proportion of not accepting mRNA technology. The highest proportion from Europe and the Americas would only accept a vaccine produced by certain countries. The foremost important vaccine characteristic influencing vaccine choice is adverse reactions (40.6%; 95% CI 39.3-41.9) of a vaccine and effectiveness threshold (35.1%; 95% CI 33.9-36.4). CONCLUSIONS: The inter-regional and individual country disparities in COVID-19 vaccine hesitancy highlight the importance of designing an efficient plan for the delivery of interventions dynamically tailored to the local population.


Asunto(s)
Vacunas contra la COVID-19 , Intención , Vacunación , Adolescente , Adulto , Anciano , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19/administración & dosificación , Estudios Transversales , Femenino , Salud Global , Humanos , Masculino , Persona de Mediana Edad , Factores Socioeconómicos , Encuestas y Cuestionarios , Vacunación/psicología , Vacunación/estadística & datos numéricos , Adulto Joven
10.
BMJ Case Rep ; 14(10)2021 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-34625443

RESUMEN

A 50-year-old Indian woman presented with acute dysphasia, left upper limb numbness and thrombocytopenia 12 days after receiving the ChAdOx1 nCoV-19 vaccine (AstraZeneca/Vaxzevria). MRI of the brain was unremarkable. Microangiopathic haemolytic anaemia with thrombocytopenia was noted on her peripheral blood film. A diagnosis of thrombotic thrombocytopenic purpura (TTP) was confirmed through the findings of absent ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity and markedly raised titre of ADAMTS13 autoantibodies. Prompt treatment with plasma exchange, adjunctive steroids and rituximab was commenced. A remission of TTP was achieved and she was discharged 3 weeks after admission. While other immune-mediated conditions have been documented after receipt of the vaccine, this report highlights the first case of immune-mediated TTP diagnosed after administration of the ChAdOx1 nCoV-19 vaccine.


Asunto(s)
Púrpura Trombocitopénica Trombótica , Vacunas , Vacunas contra la COVID-19 , Femenino , Humanos , Persona de Mediana Edad , Intercambio Plasmático , Púrpura Trombocitopénica Trombótica/inducido químicamente , Púrpura Trombocitopénica Trombótica/diagnóstico , Púrpura Trombocitopénica Trombótica/tratamiento farmacológico , Rituximab/efectos adversos
11.
BMJ Case Rep ; 14(10)2021 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-34625447

RESUMEN

The global COVID-19 pandemic remains challenging with efforts for community vaccination the primary strategy to control transmission and disease sequalae in the mid to long term. While several candidate vaccines have been approved for use, there is an ongoing discussion regarding potential vaccine-related adverse events. Notably, thrombotic thrombocytopaenia has been reported following ChAdOx1 nCov-19 (AstraZeneca) vaccination. We report the first known case of takotsubo (stress) cardiomyopathy 4 days after administration of the ChAdOx1 nCoV-19 vaccine in a 72-year-old man. While this condition remains one primarily seen in females, our case represents a new trigger that warrants careful consideration when assessing patients presenting with acute coronary syndromes following ChAdOx1 nCoV-19 vaccination.


Asunto(s)
COVID-19 , Cardiomiopatías , Anciano , Vacunas contra la COVID-19 , Femenino , Humanos , Masculino , Pandemias , SARS-CoV-2 , Vacunación/efectos adversos
12.
Ann Acad Med Singap ; 50(9): 703-711, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34625758

RESUMEN

INTRODUCTION: Vaccination remains a key strategy to living endemically with COVID-19. The Pfizer-BioNTech COVID-19 vaccine was first granted interim authorisation for use in Singapore in December 2020. With overseas studies published about the safety and side effect profiles of mRNA COVID-19 vaccines focusing mainly on non-Asian populations, we described the side effects of Pfizer-BioNTech COVID-19 vaccination experienced by the healthcare workers (HCWs) in a tertiary hospital in Singapore. METHODS: Data were obtained from the Occupational Health Clinic (OHC) at the National University Hospital in Singapore, which monitored staff for any adverse effects within 30 minutes post vaccination on-site and any adverse effects after that. A cross-sectional study among the vaccinated HCWs was conducted using an online survey, which established basic demographics, histories of allergies or atopic disorders, and adverse events encountered after dose 1 and dose 2 of vaccination. RESULTS: No anaphylaxis was reported. Most common symptom was giddiness (32.7%) experienced by HCWs within 30 minutes. Adverse events attended post-vaccination by OHC were generally mild and self-limiting. From the survey, odds of experiencing an adverse event after dose 2 was significantly higher than after the first dose, especially for fever/chills (odds ratio [OR] 22.5). Fever/chills, injection site reactions, headache, aches and pains, and feeling unwell were significantly more common in HCWs below 60 years compared to those ≥60 years. An allergy to food (adjusted OR 2.7) and a history of eczema/sensitive skin (adjusted OR 2.6) were associated with a skin reaction not at injection site. CONCLUSION: The side effects experienced after Pfizer-BioNTech COVID-19 vaccines are generally self-limiting and mild, with no anaphylaxis reported.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Estudios Transversales , Personal de Salud , Humanos , SARS-CoV-2 , Singapur/epidemiología , Centros de Atención Terciaria , Vacunación
13.
Pan Afr Med J ; 39: 197, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34603578

RESUMEN

The COVID-19 pandemic has changed the world in so many ways since 2019 when the first case was recorded. COVID-19 pandemic has impacted negatively on economy, health, education and infrastructure globally. COVID-19 vaccine was developed with the aim of stopping the pandemic and allowing the rebuilding of our societies and economies. The vaccine was rolled out in December 2020 and the distribution plan appears to be skewed in favour of high income countries. This paper highlights the need for consideration of the principles of equity and universal health coverage in the distribution plan of the vaccine. It emphasizes the need to ensure that the interests of citizens of developing and low income countries are well protected. The paper concludes that issues of disparity in economic status of countries entering agreement with the vaccine manufacturing companies, absence of logistic support among others should not be a barrier to ensuring equitable access to vaccine for all consistent with the sustainable development goal 3.7.


Asunto(s)
Vacunas contra la COVID-19/provisión & distribución , COVID-19/prevención & control , Disparidades en Atención de Salud/economía , Cobertura Universal del Seguro de Salud/economía , Vacunas contra la COVID-19/economía , Países en Desarrollo , Industria Farmacéutica/economía , Salud Global , Equidad en Salud , Accesibilidad a los Servicios de Salud/economía , Humanos , Factores Socioeconómicos
14.
Rev Invest Clin ; 73(5): 329-334, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34609368

RESUMEN

Since December 2019, when severe acute respiratory syndrome coronavirus 2 emerged in Wuhan, China, this virus and the resulting disease, coronavirus disease (COVID-19), has spread worldwide. What has occurred in this year and a half goes beyond anything we have dealt with, as humankind, in the past two centuries, perhaps obscured only by war. An incredible number of articles, whether scientific or in the press, have been published, making it impossible to discern between what is biological and what is social in nature. Here, we aim to reflect on the basic structure of the virus and associate its behavior to that of determining factors of the human condition that may be modifiable soon. Needless to say, we find our effort clearly incomplete, and that both scientific and social aspects regarding COVID-19 or any other pandemic encountered in the future, will be constantly changing, from their beginning to their end.


Asunto(s)
COVID-19/epidemiología , SARS-CoV-2/aislamiento & purificación , COVID-19/transmisión , COVID-19/virología , Vacunas contra la COVID-19/administración & dosificación , Humanos , Pandemias
15.
Acta Med Indones ; 53(3): 326-330, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-34611073

RESUMEN

SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate of COVID-19. Various vaccination platforms are produced, such as inactivated, viral vector, mRNA, and protein subunit. The vaccination booster program with mRNA platform (Moderna) was launched by the Indonesian government to give better protection for health care workers, particularly from delta variant. In this case report, we discuss one of the typical side effects of Moderna vaccine, which is referred to as the COVID arm.


Asunto(s)
Acetaminofén/administración & dosificación , Vacunas contra la COVID-19 , COVID-19/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Hipersensibilidad Retardada , Piel/patología , Analgésicos no Narcóticos/administración & dosificación , Biopsia/métodos , COVID-19/epidemiología , Vacunas contra la COVID-19/administración & dosificación , Vacunas contra la COVID-19/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/fisiopatología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/terapia , Femenino , Fiebre/tratamiento farmacológico , Fiebre/etiología , Humanos , Hipersensibilidad Retardada/inducido químicamente , Hipersensibilidad Retardada/fisiopatología , Hipersensibilidad Retardada/terapia , Reacción en el Punto de Inyección/diagnóstico , Reacción en el Punto de Inyección/etiología , Reacción en el Punto de Inyección/fisiopatología , Persona de Mediana Edad , Médicos , SARS-CoV-2 , Resultado del Tratamiento , Vacunación/métodos
16.
Rev Esc Enferm USP ; 55: e20210193, 2021.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-34617954

RESUMEN

OBJECTIVE: To reflect on the perception of nurses working in Primary Health Care about the development of the COVID-19 vaccination campaign. METHOD: This is a participatory action qualitative study, based on the methodological theoretical precepts by Paulo Freire, which consists of three interconnected phases: Thematic Research, Coding and Decoding, and Critical Unveiling. Three virtual Culture Circles were held between February and March 2021, with 11 nurses from Primary Health Care, residing in Santa Catarina, Brazil. RESULTS: Nurses defined two themes for discussion in the Culture Circle: 1. Matches in the COVID-19 vaccination campaign, representing the potentialities; 2. Mismatches in the COVID-19 vaccination campaign, in which the weaknesses were revealed. CONCLUSION: Nurses indicated potentialities such as teamwork, with hope, motivation, and joy in the vaccination campaign operationalization, through innovative and old actions. They also highlighted weaknesses such as lack of specific training and communication, difficulties with recording and application of the immunobiological, mentioning the anti-vaccine movement and the intense work, which requires adjustments to improve assistance to the population.


Asunto(s)
COVID-19 , Enfermeras y Enfermeros , Vacunas contra la COVID-19 , Humanos , Programas de Inmunización , Atención Primaria de Salud , SARS-CoV-2
17.
Zhonghua Nei Ke Za Zhi ; 60(7): 615-618, 2021 Jul 01.
Artículo en Chino | MEDLINE | ID: mdl-34619837

RESUMEN

The outbreak of coronavirus disease 2019(COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. SARS-CoV-2 vaccination is currently being actively promoted all over the world, which would serve a promising measure to combat the epidemic. HIV-infected patients manifest varying degrees of immunodeficiency and chronic inflammation, who may require a special consideration on vaccine types and timing of immunization depending on specific clinical situations. The present recommendation provides reference for SARS-CoV-2 vaccination in HIV-infected patients.


Asunto(s)
COVID-19 , Infecciones por VIH , Vacunas contra la COVID-19 , Infecciones por VIH/complicaciones , Humanos , SARS-CoV-2 , Vacunación
18.
BMJ Case Rep ; 14(10)2021 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-34620638

RESUMEN

With increasing presentations of headaches following COVID-19 vaccination, we present one of the UK's earliest proven cases of vaccine-induced thrombotic thrombocytopaenia (VITT), with the aim of giving colleagues a case to compare other patients against. Our patient was a 48-year-old man who presented with frank haematuria, a widespread petechial rash, and headaches, 2 weeks after receiving the first dose of the Oxford AstraZeneca ChAdOx1 nCoV-19 vaccine. He had a platelet count of 14×109/L and an extensive cerebral venous sinus thrombosis (CVST) with subarachnoid haemorrhage on imaging. He developed localising neurological signs and experienced a cardiopulmonary arrest. He was successfully resuscitated and transferred to a tertiary care centre for urgent thrombectomy. This case illustrates how the diagnosis of VITT should be based on the platelet count and imaging-and how patients with VITT should be cared for in centres with urgent neurosurgical and interventional radiology services.


Asunto(s)
COVID-19 , Exantema , Trombosis de los Senos Intracraneales , Vacunas contra la COVID-19 , Cefalea , Hematuria , Humanos , Masculino , Persona de Mediana Edad , SARS-CoV-2 , Vacunación
19.
Euro Surveill ; 26(39)2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34596016

RESUMEN

COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (-26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.


Asunto(s)
COVID-19 , Coinfección , Vacunas , Vacunas contra la COVID-19 , Humanos , SARS-CoV-2 , España/epidemiología
20.
Euro Surveill ; 26(39)2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34596018

RESUMEN

BackgroundTo mitigate SARS-CoV-2 transmission risks from international air travellers, many countries implemented a combination of up to 14 days of self-quarantine upon arrival plus PCR testing in the early stages of the COVID-19 pandemic in 2020.AimTo assess the effectiveness of quarantine and testing of international travellers to reduce risk of onward SARS-CoV-2 transmission into a destination country in the pre-COVID-19 vaccination era.MethodsWe used a simulation model of air travellers arriving in the United Kingdom from the European Union or the United States, incorporating timing of infection stages while varying quarantine duration and timing and number of PCR tests.ResultsQuarantine upon arrival with a PCR test on day 7 plus a 1-day delay for results can reduce the number of infectious arriving travellers released into the community by a median 94% (95% uncertainty interval (UI): 89-98) compared with a no quarantine/no test scenario. This reduction is similar to that achieved by a 14-day quarantine period (median > 99%; 95% UI: 98-100). Even shorter quarantine periods can prevent a substantial amount of transmission; all strategies in which travellers spend at least 5 days (mean incubation period) in quarantine and have at least one negative test before release are highly effective (median reduction 89%; 95% UI: 83-95)).ConclusionThe effect of different screening strategies impacts asymptomatic and symptomatic individuals differently. The choice of an optimal quarantine and testing strategy for unvaccinated air travellers may vary based on the number of possible imported infections relative to domestic incidence.


Asunto(s)
COVID-19 , SARS-CoV-2 , Vacunas contra la COVID-19 , Humanos , Pandemias , Cuarentena , Reino Unido/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...